Luminex Corp. (NASDAQ:LMNX) CEO Nachum Shamir purchased 6,000 shares of the stock in a transaction dated Thursday, November 3rd. The shares were purchased at an average price of $18.22 per share, for a total transaction of $109,320.00. Following the completion of the transaction, the chief executive officer now owns 105,010 shares in the company, valued at approximately $1,913,282.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Luminex Corp. (NASDAQ:LMNX) opened at 20.49 on Thursday. The firm has a market capitalization of $893.04 million, a PE ratio of 23.63 and a beta of 0.57. The company has a 50 day moving average price of $21.58 and a 200-day moving average price of $21.09. Luminex Corp. has a one year low of $17.29 and a one year high of $23.75.

Luminex Corp. (NASDAQ:LMNX) last announced its earnings results on Monday, October 31st. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.12 by $0.09. The business had revenue of $71.20 million for the quarter, compared to the consensus estimate of $68.90 million. Luminex Corp. had a return on equity of 11.95% and a net margin of 14.51%. Luminex Corp.’s revenue was up 17.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.22 EPS. On average, equities analysts predict that Luminex Corp. will post $0.52 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors increased its position in shares of Luminex Corp. by 0.3% in the second quarter. Nationwide Fund Advisors now owns 30,197 shares of the company’s stock valued at $611,000 after buying an additional 78 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Luminex Corp. by 0.6% in the second quarter. Louisiana State Employees Retirement System now owns 17,100 shares of the company’s stock valued at $346,000 after buying an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of Luminex Corp. by 1.7% in the third quarter. Municipal Employees Retirement System of Michigan now owns 8,560 shares of the company’s stock valued at $194,000 after buying an additional 140 shares during the last quarter. Creative Planning increased its position in shares of Luminex Corp. by 1.6% in the third quarter. Creative Planning now owns 8,923 shares of the company’s stock valued at $203,000 after buying an additional 141 shares during the last quarter. Finally, Guggenheim Capital LLC increased its position in shares of Luminex Corp. by 0.3% in the second quarter. Guggenheim Capital LLC now owns 59,035 shares of the company’s stock valued at $1,194,000 after buying an additional 153 shares during the last quarter. 78.20% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on the company. Avondale Partners assumed coverage on Luminex Corp. in a research report on Wednesday, October 12th. They set an “outperform” rating and a $27.00 price target on the stock. Zacks Investment Research cut Luminex Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Jefferies Group lifted their price target on Luminex Corp. from $21.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 28th. JPMorgan Chase & Co. upgraded Luminex Corp. from an “underweight” rating to a “neutral” rating and lifted their price target for the company from $18.00 to $22.00 in a research report on Thursday, August 18th. Finally, William Blair reiterated a “market perform” rating on shares of Luminex Corp. in a research report on Tuesday, November 1st. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Luminex Corp. has a consensus rating of “Hold” and a consensus target price of $23.00.

Luminex Corp. Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

5 Day Chart for NASDAQ:LMNX

Receive News & Stock Ratings for Luminex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corp. and related stocks with our FREE daily email newsletter.